In a surprising move, GSK recently pulled multiple myeloma therapy Blenrep off the U.S. market just 15 days after the drug flunked a confirmatory trial. …

Eli Lilly is entering 2023 still riding a high from last year. Amid an expansion spree thanks to launches such as Mounjaro in diabetes, the company is gearing …

With many of the world’s top-selling drugs speeding toward patent expirations over the next few years, pharmaceutical companies are hurrying to identify replacements. In its …

As AstraZeneca fights to defend its aging two-drug inhaler Symbicort against generics, the company has a new approval to bolster its respiratory business. Wednesday, the …

Last month, POCN, the largest network of physician associates and nurse practitioners, launched the first HIV Center of Excellence in conjunction with HIV Awareness Month. …

It’s near the end of the game and Astellas is running out of timeouts as it tries to stave off generic competition for its scanning …

In a closely watched patent dispute playing out at the U.S. Supreme Court, Amgen has drummed up support from fellow drugmakers large and small, plus …

Novartis has decided to end a classic generic pay-for-delay legal battle with a series of settlements. The Swiss pharma will pay altogether $245 million in …

A scathing congressional report has detailed communications described as “inappropriate” and “atypical” between Biogen and the FDA regarding the approval of Alzheimer’s disease drug Aduhelm …

The FDA’s cadre of Indian manufacturing investigators has dished up yet another warning letter. This time, the dishonor goes to the local branch of Dutch …